Howard Capital Management Group LLC Lowers Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Howard Capital Management Group LLC reduced its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 0.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,512 shares of the financial services provider’s stock after selling 80 shares during the period. Howard Capital Management Group LLC’s holdings in iShares Biotechnology ETF were worth $5,753,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Hsbc Holdings PLC raised its stake in iShares Biotechnology ETF by 47.1% in the second quarter. Hsbc Holdings PLC now owns 3,670 shares of the financial services provider’s stock valued at $504,000 after purchasing an additional 1,175 shares in the last quarter. AE Wealth Management LLC raised its position in shares of iShares Biotechnology ETF by 10.7% during the 2nd quarter. AE Wealth Management LLC now owns 2,034 shares of the financial services provider’s stock valued at $279,000 after buying an additional 196 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of iShares Biotechnology ETF by 34.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,622 shares of the financial services provider’s stock worth $684,000 after acquiring an additional 1,177 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of iShares Biotechnology ETF by 2.6% during the 2nd quarter. Bank of Montreal Can now owns 36,198 shares of the financial services provider’s stock worth $5,086,000 after acquiring an additional 920 shares during the last quarter. Finally, Prairie Wealth Advisors Inc. grew its position in iShares Biotechnology ETF by 6.0% in the second quarter. Prairie Wealth Advisors Inc. now owns 1,765 shares of the financial services provider’s stock worth $242,000 after acquiring an additional 100 shares in the last quarter. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

NASDAQ IBB opened at $136.10 on Wednesday. The stock’s 50-day simple moving average is $136.15 and its two-hundred day simple moving average is $141.84. iShares Biotechnology ETF has a twelve month low of $123.60 and a twelve month high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were issued a dividend of $0.0624 per share. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.